Titre : Immunosuppresseurs

Immunosuppresseurs : Questions médicales fréquentes

{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Immunosuppresseurs : Questions médicales les plus fréquentes", "headline": "Immunosuppresseurs : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Immunosuppresseurs : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-27", "dateModified": "2025-04-22", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Immunosuppresseurs" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Facteurs immunologiques", "url": "https://questionsmedicales.fr/mesh/D007155", "about": { "@type": "MedicalCondition", "name": "Facteurs immunologiques", "code": { "@type": "MedicalCode", "code": "D007155", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.477" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Inhibiteurs du complément", "alternateName": "Complement Inactivating Agents", "url": "https://questionsmedicales.fr/mesh/D051056", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs du complément", "code": { "@type": "MedicalCode", "code": "D051056", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.477.656.500" } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Antagonistes du récepteur B2 de la bradykinine", "alternateName": "Bradykinin B2 Receptor Antagonists", "url": "https://questionsmedicales.fr/mesh/D065094", "about": { "@type": "MedicalCondition", "name": "Antagonistes du récepteur B2 de la bradykinine", "code": { "@type": "MedicalCode", "code": "D065094", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.477.656.500.500" } } } ] }, { "@type": "MedicalWebPage", "name": "Inhibiteurs des interleukines", "alternateName": "Interleukin Inhibitors", "url": "https://questionsmedicales.fr/mesh/D000088902", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs des interleukines", "code": { "@type": "MedicalCode", "code": "D000088902", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.477.656.563" } } }, { "@type": "MedicalWebPage", "name": "Inhibiteurs de l'interleukine-6", "alternateName": "Interleukin-6 Inhibitors", "url": "https://questionsmedicales.fr/mesh/D000093242", "about": { "@type": "MedicalCondition", "name": "Inhibiteurs de l'interleukine-6", "code": { "@type": "MedicalCode", "code": "D000093242", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.477.656.594" } } }, { "@type": "MedicalWebPage", "name": "Modulateurs des récepteurs de la sphingosine 1 phosphate", "alternateName": "Sphingosine 1 Phosphate Receptor Modulators", "url": "https://questionsmedicales.fr/mesh/D000081243", "about": { "@type": "MedicalCondition", "name": "Modulateurs des récepteurs de la sphingosine 1 phosphate", "code": { "@type": "MedicalCode", "code": "D000081243", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D27.505.696.477.656.875" } } } ], "about": { "@type": "MedicalCondition", "name": "Immunosuppresseurs", "alternateName": "Immunosuppressive Agents", "code": { "@type": "MedicalCode", "code": "D007166", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Koichi Kamei", "url": "https://questionsmedicales.fr/author/Koichi%20Kamei", "affiliation": { "@type": "Organization", "name": "Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan. kamei-k@ncchd.go.jp." } }, { "@type": "Person", "name": "Masao Ogura", "url": "https://questionsmedicales.fr/author/Masao%20Ogura", "affiliation": { "@type": "Organization", "name": "Division of Nephrology and Rheumatology, National Center for Child Health and Development, Tokyo, Japan." } }, { "@type": "Person", "name": "Kensuke Shoji", "url": "https://questionsmedicales.fr/author/Kensuke%20Shoji", "affiliation": { "@type": "Organization", "name": "Division of Infectious Diseases, National Center for Child Health and Development, Tokyo, Japan." } }, { "@type": "Person", "name": "Shuichi Ito", "url": "https://questionsmedicales.fr/author/Shuichi%20Ito", "affiliation": { "@type": "Organization", "name": "Department of Pediatrics, Yokohama City University Hospital, Kanagawa, Japan." } }, { "@type": "Person", "name": "Dorota Iwaszkiewicz-Grześ", "url": "https://questionsmedicales.fr/author/Dorota%20Iwaszkiewicz-Grze%C5%9B", "affiliation": { "@type": "Organization", "name": "Department of Medical Immunology, Faculty of Medicine, Medical University of Gdansk, ul. Dębinki 7, 80-210 Gdańsk, Poland." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Case report: Managing pemphigus foliaceus using apremilast without systemic glucocorticosteroids or immunosuppressive agents.", "datePublished": "2024-07-30", "url": "https://questionsmedicales.fr/article/39139566", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2024.1408116" } }, { "@type": "ScholarlyArticle", "name": "Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis.", "datePublished": "2023-10-13", "url": "https://questionsmedicales.fr/article/37901212", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2023.1232244" } }, { "@type": "ScholarlyArticle", "name": "Statins in Kidney Transplant Recipients: Usage, All-Cause Mortality, and Interactions with Maintenance Immunosuppressive Agents.", "datePublished": "2023-03-09", "url": "https://questionsmedicales.fr/article/36890643", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1681/ASN.0000000000000112" } }, { "@type": "ScholarlyArticle", "name": "Immunosuppressive Agent Options for Primary Nephrotic Syndrome: A Review of Network Meta-Analyses and Cost-Effectiveness Analysis.", "datePublished": "2023-03-17", "url": "https://questionsmedicales.fr/article/36984602", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/medicina59030601" } }, { "@type": "ScholarlyArticle", "name": "The usage of immunosuppressant agents and secondary infections in patients with COVID-19 in the intensive care unit: a retrospective study.", "datePublished": "2024-09-09", "url": "https://questionsmedicales.fr/article/39251824", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1038/s41598-024-71912-3" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Actions chimiques et utilisations", "item": "https://questionsmedicales.fr/mesh/D020164" }, { "@type": "ListItem", "position": 3, "name": "Actions pharmacologiques", "item": "https://questionsmedicales.fr/mesh/D020228" }, { "@type": "ListItem", "position": 4, "name": "Effets physiologiques des médicaments", "item": "https://questionsmedicales.fr/mesh/D045505" }, { "@type": "ListItem", "position": 5, "name": "Facteurs immunologiques", "item": "https://questionsmedicales.fr/mesh/D007155" }, { "@type": "ListItem", "position": 6, "name": "Immunosuppresseurs", "item": "https://questionsmedicales.fr/mesh/D007166" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Immunosuppresseurs - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Immunosuppresseurs", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-04-28", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Immunosuppresseurs", "description": "Comment diagnostiquer une nécessité d'immunosuppresseurs ?\nQuels tests sont utilisés pour évaluer l'immunité ?\nQuels signes indiquent un besoin d'immunosuppresseurs ?\nComment évaluer le risque de rejet d'organe ?\nQuels symptômes nécessitent un traitement immunosuppresseur ?", "url": "https://questionsmedicales.fr/mesh/D007166?page=2#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Immunosuppresseurs", "description": "Quels sont les effets secondaires des immunosuppresseurs ?\nComment reconnaître une infection due à l'immunosuppression ?\nQuels symptômes d'allergie peuvent survenir ?\nLes immunosuppresseurs causent-ils des troubles digestifs ?\nQuels signes indiquent une réaction indésirable ?", "url": "https://questionsmedicales.fr/mesh/D007166?page=2#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Immunosuppresseurs", "description": "Comment prévenir les infections sous immunosuppression ?\nQuelles précautions alimentaires prendre ?\nComment gérer le stress pendant le traitement ?\nQuels examens de suivi sont nécessaires ?\nComment éviter les interactions médicamenteuses ?", "url": "https://questionsmedicales.fr/mesh/D007166?page=2#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Immunosuppresseurs", "description": "Quels types d'immunosuppresseurs existent ?\nComment sont administrés les immunosuppresseurs ?\nQuelle est la durée du traitement immunosuppresseur ?\nComment ajuster la posologie des immunosuppresseurs ?\nQuels sont les traitements alternatifs aux immunosuppresseurs ?", "url": "https://questionsmedicales.fr/mesh/D007166?page=2#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Immunosuppresseurs", "description": "Quelles sont les complications possibles des immunosuppresseurs ?\nComment reconnaître une infection grave ?\nLes immunosuppresseurs augmentent-ils le risque de cancer ?\nQuels troubles métaboliques peuvent survenir ?\nComment gérer les complications liées aux immunosuppresseurs ?", "url": "https://questionsmedicales.fr/mesh/D007166?page=2#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Immunosuppresseurs", "description": "Quels facteurs augmentent le besoin d'immunosuppresseurs ?\nComment l'âge influence-t-il le traitement ?\nLe mode de vie affecte-t-il l'immunosuppression ?\nQuels médicaments augmentent le risque d'interactions ?\nLes antécédents familiaux influencent-ils le traitement ?", "url": "https://questionsmedicales.fr/mesh/D007166?page=2#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une nécessité d'immunosuppresseurs ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'évaluation clinique et des tests sanguins pour évaluer l'auto-immunité." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'immunité ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests comme le dosage des anticorps et des lymphocytes T sont couramment utilisés." } }, { "@type": "Question", "name": "Quels signes indiquent un besoin d'immunosuppresseurs ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des inflammations chroniques ou des éruptions cutanées peuvent indiquer ce besoin." } }, { "@type": "Question", "name": "Comment évaluer le risque de rejet d'organe ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'évaluation se fait par des tests de compatibilité et des marqueurs immunologiques." } }, { "@type": "Question", "name": "Quels symptômes nécessitent un traitement immunosuppresseur ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme la fatigue extrême ou des douleurs articulaires peuvent nécessiter un traitement." } }, { "@type": "Question", "name": "Quels sont les effets secondaires des immunosuppresseurs ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires incluent infections, fatigue, et troubles gastro-intestinaux." } }, { "@type": "Question", "name": "Comment reconnaître une infection due à l'immunosuppression ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme fièvre, frissons ou douleurs inhabituelles peuvent indiquer une infection." } }, { "@type": "Question", "name": "Quels symptômes d'allergie peuvent survenir ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des éruptions cutanées, démangeaisons ou gonflements peuvent être des signes d'allergie." } }, { "@type": "Question", "name": "Les immunosuppresseurs causent-ils des troubles digestifs ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des nausées, vomissements ou diarrhées peuvent survenir avec certains immunosuppresseurs." } }, { "@type": "Question", "name": "Quels signes indiquent une réaction indésirable ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des douleurs abdominales ou des saignements peuvent signaler une réaction." } }, { "@type": "Question", "name": "Comment prévenir les infections sous immunosuppression ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il est essentiel de se faire vacciner et d'éviter les contacts avec des personnes malades." } }, { "@type": "Question", "name": "Quelles précautions alimentaires prendre ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Évitez les aliments crus et assurez-vous que les aliments sont bien cuits pour prévenir les infections." } }, { "@type": "Question", "name": "Comment gérer le stress pendant le traitement ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques de relaxation et un soutien psychologique peuvent aider à gérer le stress." } }, { "@type": "Question", "name": "Quels examens de suivi sont nécessaires ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des examens réguliers de la fonction rénale et des tests sanguins sont nécessaires pour le suivi." } }, { "@type": "Question", "name": "Comment éviter les interactions médicamenteuses ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Informez toujours votre médecin de tous les médicaments que vous prenez pour éviter les interactions." } }, { "@type": "Question", "name": "Quels types d'immunosuppresseurs existent ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les principaux types incluent les corticostéroïdes, les inhibiteurs de calcineurine et les agents biologiques." } }, { "@type": "Question", "name": "Comment sont administrés les immunosuppresseurs ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils peuvent être administrés par voie orale, intraveineuse ou sous-cutanée selon le médicament." } }, { "@type": "Question", "name": "Quelle est la durée du traitement immunosuppresseur ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La durée varie selon la maladie, allant de quelques mois à plusieurs années." } }, { "@type": "Question", "name": "Comment ajuster la posologie des immunosuppresseurs ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La posologie est ajustée en fonction des résultats des tests sanguins et de la réponse clinique." } }, { "@type": "Question", "name": "Quels sont les traitements alternatifs aux immunosuppresseurs ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Des traitements alternatifs incluent des thérapies biologiques et des médicaments anti-inflammatoires." } }, { "@type": "Question", "name": "Quelles sont les complications possibles des immunosuppresseurs ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des infections graves, des cancers et des troubles métaboliques." } }, { "@type": "Question", "name": "Comment reconnaître une infection grave ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme une forte fièvre, des frissons ou une confusion peuvent indiquer une infection grave." } }, { "@type": "Question", "name": "Les immunosuppresseurs augmentent-ils le risque de cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'utilisation prolongée d'immunosuppresseurs peut augmenter le risque de certains cancers." } }, { "@type": "Question", "name": "Quels troubles métaboliques peuvent survenir ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles comme le diabète ou l'hypertension peuvent survenir avec certains immunosuppresseurs." } }, { "@type": "Question", "name": "Comment gérer les complications liées aux immunosuppresseurs ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion implique un suivi régulier, des ajustements de traitement et une surveillance des symptômes." } }, { "@type": "Question", "name": "Quels facteurs augmentent le besoin d'immunosuppresseurs ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Des antécédents de maladies auto-immunes ou de transplantation augmentent ce besoin." } }, { "@type": "Question", "name": "Comment l'âge influence-t-il le traitement ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Les personnes âgées peuvent avoir un risque accru d'effets secondaires et nécessiter des ajustements." } }, { "@type": "Question", "name": "Le mode de vie affecte-t-il l'immunosuppression ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie sain peut réduire les risques d'infections et améliorer la réponse au traitement." } }, { "@type": "Question", "name": "Quels médicaments augmentent le risque d'interactions ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Certains antibiotiques et antifongiques peuvent interagir avec les immunosuppresseurs." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils le traitement ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies auto-immunes peuvent augmenter le risque de développer des maladies similaires." } } ] } ] }

Sources (10000 au total)

Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis.

Various immunosuppressive regimens have been developed for the treatment of lupus nephritis (LN). This study aimed to compare the efficacy and safety of immunosuppressive regimens in adults with LN.... We systematically searched the PubMed, Embase, and Cochrane Central Register of Controlled Trials databases, including conference proceedings, trial registries, and reference lists, from inception unt... Sixty-two trials reported in 172 studies involving 6,936 patients were included in the network meta-analysis. The combination of tacrolimus (TAC), mycophenolate mofetil (MMF), and glucocorticoid (GC) ... This study showed that a combination of TAC, MMF and GC was the best regimen for improving the total remission rate. The optimal regimen for specific outcomes should be highlighted for high-risk patie...

Statins in Kidney Transplant Recipients: Usage, All-Cause Mortality, and Interactions with Maintenance Immunosuppressive Agents.

Cardiovascular diseases account for 32% of deaths among kidney transplant recipients. Statin therapy is common in this population. However, its effect on mortality prevention remains unclear among kid... Cardiovascular diseases are the leading cause of mortality in kidney transplant (KT) recipients, accounting for 32% of deaths. Statins are widely used in KT recipients, but effectiveness for preventin... We studied statin use and mortality among 58,264 adults (18 years or older) who received single kidneys between 2006 and 2016 and had Medicare part A/B/D. Statin use was ascertained from Medicare pres... Statin use increased from 45.5% at KT to 58.2% at 1-year post-KT to 70.9% at 5-year post-KT. We observed 9785 deaths over 236,944 person-years. Overall, statin use was significantly associated with lo... Real-world evidence supports statin therapy for reducing all-cause mortality in KT recipients. Effectiveness might be greater when combined with mTOR inhibitor-based immunosuppression....

Immunogenicity and safety of SARS-CoV-2 mRNA vaccine in patients with nephrotic syndrome receiving immunosuppressive agents.

As there are no large-scale reports of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA vaccination in patients with nephrotic syndrome using immunosuppressive agents, we conducted th... SARS-CoV-2 mRNA vaccines were administered to patients with nephrotic syndrome receiving immunosuppressive agents. The titers of SARS-CoV-2 spike protein receptor-binding domain antibodies were measur... We enrolled 40 patients and evaluated vaccine immunogenicity in 35 of them. Seroconversion (> 0.8 U/mL) was achieved in all patients, and the median antibody titer was 598 U/mL (interquartile range, 8... The SARS-CoV-2 mRNA vaccine was immunogenic in patients with nephrotic syndrome using immunosuppressive agents, although the use of MMF and low levels of serum IgG were associated with lower antibody ...

Comparison of effects of aminosalicylic acid, glucocorticoids and immunosuppressive agents on the expression of multidrug-resistant genes in ulcerative colitis.

To compare the effects of aminosalicylic acid, glucocorticoids and immunosuppressants on the expression levels of multidrug resistance genes in patients with ulcerative colitis (UC), with the aim of p...

Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors.

In solid organ transplant recipients, skin cancer risk associated with posttransplant immunosuppression has been well-described, and screening practices generally reflect these risks. In addition to a...

The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real-world, multicenter, retrospective study.

Immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) are often managed via immunosuppressive agents (ISAs); however, their impact on ICI efficacy is not well studi... This is a real-world, multicenter, retrospective cohort study of patients with advanced melanoma who received ICIs (n = 370). Overall survival (OS) and time to treatment failure (TTF) from the time of... Overall, irAEs of any grade and of grade ≥3 occurred in 57% and 23% of patients, respectively. Thirty-seven percent of patients received steroids, and 3% received other ISAs. Median OS was longest amo... These findings in patients with melanoma who were treated with ICIs suggest that the use of SSs or ISAs for the management of irAEs is not associated with inferior disease outcomes, which supports the...

Reporting of COVID-19 Reinfection and Potential Role of Immunosuppressant/Immunomodulating Agents: A Cross-Sectional Observational Analysis Based on a Spontaneous Reporting Database.

The enduring presence of COVID-19 and subsequent increasing incidence of COVID-19 reinfection has prompted evaluation of associated risk factors, particularly the role of immunosuppression.... The objective of this study was to characterize cases indicative of COVID-19 reinfection with respect to their reported use of immunosuppressant/immunomodulating agents.... This cross-sectional observational study leveraged the Pfizer global safety database (SDB) containing adverse event data collected in association with use of Pfizer products between 1 October 2019, an... Of the cumulative total of 218,242 COVID-19 cases reported into the SDB, 4590 cases (2.1%) involving potential COVID-19 reinfection were identified. Of these 4590 cases of potential Covid-19 reinfecti... This pharmacovigilance study provides a characterization of cases indicative of COVID-19 reinfection with respect to reported use of immunosuppressant/immunomodulating agents. The observations generat...